{"success":true,"data":{"pressRelease":{"id":"110936","rtpr_id":"nGNX2fynwR","ticker":"ACRS","exchange":"NASDAQ","all_tickers":["ACRS"],"title":"Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update","author":"Globe Newswire","published_at":"2026-08-06T10:59:00.215Z","article_body":"- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate\nPotential Best-in-Class Potency Advantage and Opportunity for Extended Dosing\n-\n\n- Timelines Reaffirmed for Upcoming Top Line Results from Phase 1b\nProof-of-Concept (POC) Trials of ATI-052 and Phase 2 Trial of Bosakitug\n(ATI-045) -\n\n- Strong Cash Runway Expected to Enable Development of Pipeline Through the\nEnd of 2028 -\n\nWAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc.\n(NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on\ndeveloping novel product candidates for immuno-inflammatory diseases, today\nannounced its financial results for the second quarter of 2026 and provided a\ncorporate and clinical update.\n\n“The first half of 2026 was a period of strong execution across the\norganization, positioning Aclaris for an exciting second half of the year with\nnumerous expected key catalysts,” stated Dr. Neal Walker, Chief Executive\nOfficer and Chair of the Board of Directors of Aclaris. “We expect to\nprovide three clinical data readouts, including placebo-controlled top line\nresults from our two Phase 1b POC trials of our anti-TSLP/IL-4Rα bispecific\nantibody ATI-052 in both asthma and atopic dermatitis and the Phase 2 AD trial\nof our anti-TSLP monoclonal antibody bosakitug. Other key catalysts include\ninitiation of a Phase 2b clinical program with ATI-052 and a Phase 2b trial in\nlichen planus with modzatinib. Finally, our data presented recently at the\nFASEB Immunoreceptors and Immunotherapy conference support the best-in-class\npotential of our investigational ITK inhibitor ATI-9494, for which we expect\nto file an IND late this year.”\n\nSecond Quarter 2026 Highlights, Recent Updates and Upcoming Catalysts\n\nPipeline:\n\nBiologics: Antibody Franchise\n* Provided Positive Full Top Line Results of Phase 1a Single (SAD) and\nMultiple Ascending Dose (MAD) Trial of Investigational Bispecific\nAnti-TSLP/IL-4Rα Antibody ATI-052 Validating Potency and Potential for\nExtended Dosing: ATI-052 was well tolerated and demonstrated a favorable\nsafety profile. The combination of the strong and sustained PK duration and PD\neffect supported the potential for up to quarterly dosing. (press release here\n(https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-announces-positive-full-top-line-first))\n* Reaffirmed Expectation of Top Line Results in the Second Half of 2026 from\nTwo Ongoing Phase 1b POC Trials of ATI-052: ATI-052 is being assessed in POC\ntrials in both atopic dermatitis (AD) and asthma.\n* Confirmed Intent to Initiate a Phase 2b Program Encompassing Asthma and AD\nwith ATI-052 in the Fourth Quarter of 2026: Aclaris expects the clinical\nprogram to commence with a Phase 2b trial in asthma in the fourth quarter of\n2026. The Company also now expects to commence startup activities for a Phase\n2b trial in AD and for a proof-of-concept (POC) trial in eosinophilic\nesophagitis (EoE).\n* On Track for Expected Fourth Quarter 2026 Readout of Top Line Results from\nPhase 2 Trial of Investigational Anti-TSLP Monoclonal Antibody Bosakitug:\nEnrollment is complete in this randomized, double-blind, placebo-controlled\nPhase 2 trial designed to evaluate bosakitug in 109 patients with AD. (press\nrelease here\n(https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-completes-enrollment-phase-2-trial))\nKinase Inhibitors: ITK Franchise\n* Initiation of Phase 2b Clinical Program for Modzatinib (ATI-2138), a Potent\nand Selective Investigational Inhibitor of ITK and JAK3, Planned for the\nFourth Quarter of 2026: Aclaris intends to initiate a multi-part Phase 2b\ntrial of modzatinib in lichen planus, an unaddressed chronic, inflammatory,\nCD8-driven interface dermatitis. There are currently no approved therapies in\nthis indication. (press release here\n(https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-announces-positive-full-top-line-first))\n* On Track for Expected Fourth Quarter 2026 Filing of Investigational New Drug\n(IND) Application for ATI-9494, Aclaris’ Investigational Dual Inhibitor of\nITK and TXK: ATI-9494 has demonstrated potent blockade of Th1 and Th2\nresponses, a prolonged half-life, and high potency against ITK, potentially\nenabling low drug burden, dosing flexibility, and once daily (QD)\nadministration across a broad range of disease indications.\n* Presented Data Characterizing Potency, Selectivity, and Target Occupancy of\nATI-9494: New preclinical data presented at the 2026 Federation of American\nSocieties for Experimental Biology (FASEB) Immunoreceptors and Immunology\nScience Research Conference included results from cellular target engagement\nstudies that demonstrated potent engagement of ITK by ATI-9494 and its ability\nto block functional activation of the TCR pathway. ATI-9494 demonstrated\npotency up to 25 times greater than soquelitinib (CPI-818) across multiple\nbiochemical and functional cellular assays.\nFinancial Results\n\nLiquidity and Capital Resources\n\nAs of June 30, 2026, Aclaris had cash, cash equivalents and marketable\nsecurities of $170.6 million compared to $151.4 million as of December 31,\n2025. Subsequent to June 30, 2026, the Company sold 7.3 million shares of its\ncommon stock for aggregate gross proceeds of $40.2 million, pursuant to the\nCompany’s at-the-market (ATM) agreement with Leerink Partners LLC and Cantor\nFitzgerald & Co. Proceeds from these sales provide the Company with additional\nfunds to support the planned commencement of startup activities for the Phase\n2b trial of ATI-052 in AD and a POC trial in EoE.\n\nThe Company believes that its cash, cash equivalents and marketable securities\nwill be sufficient to fund its operations through the end of 2028, without\ngiving effect to any potential business development transactions or additional\nfinancing activities.\n\nSecond Quarter 2026 and Year-to-Date 2026\n\nNet loss was $21.5 million for the second quarter of 2026 compared to $15.4\nmillion for the second quarter of 2025. Net loss was $41.3 million for the six\nmonths ended June 30, 2026 compared to $30.5 million for the six months ended\nJune 30, 2025.\n\nTotal revenue was $1.6 million for the second quarter of 2026 compared to $1.8\nmillion for the second quarter of 2025. Total revenue was $3.6 million for the\nsix months ended June 30, 2026 compared to $3.2 million for the six months\nended June 30, 2025. The increase for the six-month period was primarily\ndriven by higher royalties earned under the Lilly and Sun Pharma license\nagreements.\n\nResearch and development (R&D) expenses were $18.1 million and $33.7 million\nfor the quarter and six months ended June 30, 2026, respectively, compared to\n$11.4 million and $23.0 million for the corresponding prior year periods. The\nincreases were primarily driven by expenses related to ATI-052, including\nproduct candidate manufacturing costs and clinical development expenses\nassociated with a Phase 1a program and Phase 1b programs in AD and asthma, as\nwell as product candidate manufacturing costs for ATI-9494.\n\nGeneral and administrative (G&A) expenses were $6.0 million and $12.8 million\nfor the quarter and six months ended June 30, 2026, respectively, compared to\n$5.4 million and $11.5 million for the prior year periods. The increases were\nprimarily due to an increase in professional and legal expenses as well as\npersonnel expenses.\n\nRevaluation of contingent consideration resulted in a $0.3 million charge for\neach of the quarter and six months ended June 30, 2026 compared to charges of\n$1.5 million and $1.8 million for the prior year periods. The decreases were\nprimarily due to changes to the probability of success for certain product\ncandidates and lower discount rates being applied to potential payments during\nthe quarter and six months ended June 30, 2025.\n\nAbout Aclaris Therapeutics, Inc.\n\nAclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company\ndeveloping a pipeline of novel product candidates to address the needs of\npatients with immuno-inflammatory diseases who lack satisfactory treatment\noptions. The Company has a multi-stage portfolio of product candidates powered\nby a robust R&D engine. For additional information, please visit\nwww.aclaristx.com and follow Aclaris on LinkedIn\n(https://www.globenewswire.com/Tracker?data=Jf5cj7CpQV5EYDwyE8-t8OqdvCdMduQv344StvXOCbAk3pIgTexL07hdgrydyERByTljmDAr_80C8FU5nPcmwyGaSrjCoXW-JEyEyq-i-WXGbhs5o39BQLDk9cdf9iBY).\n\nCautionary Note Regarding Forward-Looking Statements\n\nAny statements contained in this press release that do not describe historical\nfacts may constitute forward-looking statements as that term is defined in the\nPrivate Securities Litigation Reform Act of 1995. These statements may be\nidentified by words such as “anticipate,” “believe,” “expect,”\n“intend,” “may,” “plan,” “potential,” “will,” and similar\nexpressions, and are based on Aclaris’ current beliefs and expectations.\nThese forward-looking statements include expectations regarding its plans for\nits development programs for bosakitug, ATI-052, modzatinib (ATI-2138), and\nATI-9494, including the timing of reporting top line results from its Phase 2\ntrial of bosakitug in AD and its Phase 1b trials of ATI-052 in asthma and AD,\nthe clinical development plans for ATI-052 including the timing of initiating\na Phase 2b trial in asthma, the timing of initiating a Phase 2b trial in\nlichen planus with modzatinib, the timing to file an IND for ATI-9494, the\npotential for ATI-052 to have extended dosing, the therapeutic potential of\nits product candidates and the potential for such candidates to be\nbest-in-class, and the sufficiency of its cash, cash equivalents and\nmarketable securities to fund its operations through the end of 2028. These\nstatements involve risks and uncertainties that could cause actual results to\ndiffer materially from those reflected in such statements. Risks and\nuncertainties that may cause actual results to differ materially include\nuncertainties inherent in the conduct of preclinical and clinical studies,\nAclaris’ reliance on third parties over which it may not always have full\ncontrol, Aclaris’ ability to enter into strategic partnerships on\ncommercially reasonable terms, the uncertainty regarding the macroeconomic\nenvironment and other risks and uncertainties that are described in the\n“Risk Factors” section of Aclaris’ Annual Report on Form 10-K for the\nyear ended December 31, 2025, and other filings Aclaris makes with the U.S.\nSecurities and Exchange Commission from time to time. These documents are\navailable under the “SEC Filings” page of the “Investors” section of\nAclaris’ website at www.aclaristx.com. Any forward-looking statements speak\nonly as of the date of this press release and are based on information\navailable to Aclaris as of the date of this release, and Aclaris assumes no\nobligation to, and does not intend to, update any forward-looking statements,\nwhether as a result of new information, future events or otherwise.\n\nAclaris Therapeutics Contacts:\n\nKevin Balthaser\nChief Financial Officer\n(484) 329-2178\nkbalthaser@aclaristx.com\n\nWill Roberts\nSenior Vice President\nCorporate Communications and Investor Relations\n(484) 329-2125\nwroberts@aclaristx.com\n\n Aclaris Therapeutics, Inc. Condensed Consolidated Statements of Operations (unaudited, in thousands, except share and per share data) \n \n Three Months Ended Six Months Ended \n June 30, June 30, \n 2026 2025 2026 2025 \n \n Revenues: \n Contract research $ 356 $ 442 $ 893 $ 887 \n Licensing 1,273 1,335 2,732 2,345 \n Total revenue 1,629 1,777 3,625 3,232 \n \n Costs and expenses: \n Cost of revenue ((1)) 218 515 613 1,021 \n Research and development ((1)) 18,066 11,449 33,723 23,033 \n General and administrative ((1)) 6,048 5,386 12,791 11,525 \n Licensing 1,235 1,335 2,628 2,345 \n Revaluation of contingent consideration 300 1,500 300 1,800 \n Total costs and expenses 25,867 20,185 50,055 39,724 \n Loss from operations (24,238 ) (18,408 ) (46,430 ) (36,492 ) \n \n Other income: \n Interest income 1,761 2,018 3,275 4,184 \n Non-cash royalty income 972 961 1,826 1,794 \n Total other income 2,733 2,979 5,101 5,978 \n Net loss $ (21,505 ) $ (15,429 ) $ (41,329 ) $ (30,514 ) \n Net loss per share, basic and diluted $ (0.15 ) $ (0.13 ) $ (0.30 ) $ (0.25 ) \n Weighted average common shares outstanding, basic and diluted 142,736,848 122,580,967 135,811,921 122,486,162 \n \n (1) Amounts include stock-based compensation expense as follows: \n Cost of revenue $ (13 ) $ 190 $ 15 $ 409 \n Research and development 784 1,106 1,946 2,291 \n General and administrative 1,901 1,767 3,909 3,898 \n Total stock-based compensation expense $ 2,672 $ 3,063 $ 5,870 $ 6,598 \n \n\n\n\n Aclaris Therapeutics, Inc. Selected Consolidated Balance Sheet Data (unaudited, in thousands, except share data) \n \n June 30, December 31, \n 2026 2025 \n \n Cash, cash equivalents and marketable securities $ 170,621 $ 151,363 \n Total assets $ 179,693 $ 160,460 \n Total current liabilities $ 28,241 $ 28,645 \n Total liabilities $ 55,112 $ 57,378 \n Total stockholders' equity $ 124,581 $ 103,082 \n Common stock outstanding 139,824,273 120,499,433 \n \n\n\n\n Aclaris Therapeutics, Inc. Selected Consolidated Cash Flow Data (unaudited, in thousands) \n \n Six Months Ended \n June 30, \n 2026 2025 \n \n Net loss $ (41,329 ) $ (30,514 ) \n Depreciation and amortization 209 242 \n Stock-based compensation expense 5,870 6,598 \n Revaluation of contingent consideration 300 1,800 \n Changes in operating assets and liabilities (3,046 ) (1,176 ) \n Net cash used in operating activities $ (37,996 ) $ (23,050 ) \n \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/de2bcb21-de59-4226-bc8b-b1b747461f51)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2fynwR","title":"Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update","author":"Globe Newswire","ticker":"ACRS","created":"2026-08-06T10:59:00.215Z","tickers":["ACRS"],"exchange":"NASDAQ","article_body":"- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate\nPotential Best-in-Class Potency Advantage and Opportunity for Extended Dosing\n-\n\n- Timelines Reaffirmed for Upcoming Top Line Results from Phase 1b\nProof-of-Concept (POC) Trials of ATI-052 and Phase 2 Trial of Bosakitug\n(ATI-045) -\n\n- Strong Cash Runway Expected to Enable Development of Pipeline Through the\nEnd of 2028 -\n\nWAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc.\n(NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on\ndeveloping novel product candidates for immuno-inflammatory diseases, today\nannounced its financial results for the second quarter of 2026 and provided a\ncorporate and clinical update.\n\n“The first half of 2026 was a period of strong execution across the\norganization, positioning Aclaris for an exciting second half of the year with\nnumerous expected key catalysts,” stated Dr. Neal Walker, Chief Executive\nOfficer and Chair of the Board of Directors of Aclaris. “We expect to\nprovide three clinical data readouts, including placebo-controlled top line\nresults from our two Phase 1b POC trials of our anti-TSLP/IL-4Rα bispecific\nantibody ATI-052 in both asthma and atopic dermatitis and the Phase 2 AD trial\nof our anti-TSLP monoclonal antibody bosakitug. Other key catalysts include\ninitiation of a Phase 2b clinical program with ATI-052 and a Phase 2b trial in\nlichen planus with modzatinib. Finally, our data presented recently at the\nFASEB Immunoreceptors and Immunotherapy conference support the best-in-class\npotential of our investigational ITK inhibitor ATI-9494, for which we expect\nto file an IND late this year.”\n\nSecond Quarter 2026 Highlights, Recent Updates and Upcoming Catalysts\n\nPipeline:\n\nBiologics: Antibody Franchise\n* Provided Positive Full Top Line Results of Phase 1a Single (SAD) and\nMultiple Ascending Dose (MAD) Trial of Investigational Bispecific\nAnti-TSLP/IL-4Rα Antibody ATI-052 Validating Potency and Potential for\nExtended Dosing: ATI-052 was well tolerated and demonstrated a favorable\nsafety profile. The combination of the strong and sustained PK duration and PD\neffect supported the potential for up to quarterly dosing. (press release here\n(https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-announces-positive-full-top-line-first))\n* Reaffirmed Expectation of Top Line Results in the Second Half of 2026 from\nTwo Ongoing Phase 1b POC Trials of ATI-052: ATI-052 is being assessed in POC\ntrials in both atopic dermatitis (AD) and asthma.\n* Confirmed Intent to Initiate a Phase 2b Program Encompassing Asthma and AD\nwith ATI-052 in the Fourth Quarter of 2026: Aclaris expects the clinical\nprogram to commence with a Phase 2b trial in asthma in the fourth quarter of\n2026. The Company also now expects to commence startup activities for a Phase\n2b trial in AD and for a proof-of-concept (POC) trial in eosinophilic\nesophagitis (EoE).\n* On Track for Expected Fourth Quarter 2026 Readout of Top Line Results from\nPhase 2 Trial of Investigational Anti-TSLP Monoclonal Antibody Bosakitug:\nEnrollment is complete in this randomized, double-blind, placebo-controlled\nPhase 2 trial designed to evaluate bosakitug in 109 patients with AD. (press\nrelease here\n(https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-completes-enrollment-phase-2-trial))\nKinase Inhibitors: ITK Franchise\n* Initiation of Phase 2b Clinical Program for Modzatinib (ATI-2138), a Potent\nand Selective Investigational Inhibitor of ITK and JAK3, Planned for the\nFourth Quarter of 2026: Aclaris intends to initiate a multi-part Phase 2b\ntrial of modzatinib in lichen planus, an unaddressed chronic, inflammatory,\nCD8-driven interface dermatitis. There are currently no approved therapies in\nthis indication. (press release here\n(https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-announces-positive-full-top-line-first))\n* On Track for Expected Fourth Quarter 2026 Filing of Investigational New Drug\n(IND) Application for ATI-9494, Aclaris’ Investigational Dual Inhibitor of\nITK and TXK: ATI-9494 has demonstrated potent blockade of Th1 and Th2\nresponses, a prolonged half-life, and high potency against ITK, potentially\nenabling low drug burden, dosing flexibility, and once daily (QD)\nadministration across a broad range of disease indications.\n* Presented Data Characterizing Potency, Selectivity, and Target Occupancy of\nATI-9494: New preclinical data presented at the 2026 Federation of American\nSocieties for Experimental Biology (FASEB) Immunoreceptors and Immunology\nScience Research Conference included results from cellular target engagement\nstudies that demonstrated potent engagement of ITK by ATI-9494 and its ability\nto block functional activation of the TCR pathway. ATI-9494 demonstrated\npotency up to 25 times greater than soquelitinib (CPI-818) across multiple\nbiochemical and functional cellular assays.\nFinancial Results\n\nLiquidity and Capital Resources\n\nAs of June 30, 2026, Aclaris had cash, cash equivalents and marketable\nsecurities of $170.6 million compared to $151.4 million as of December 31,\n2025. Subsequent to June 30, 2026, the Company sold 7.3 million shares of its\ncommon stock for aggregate gross proceeds of $40.2 million, pursuant to the\nCompany’s at-the-market (ATM) agreement with Leerink Partners LLC and Cantor\nFitzgerald & Co. Proceeds from these sales provide the Company with additional\nfunds to support the planned commencement of startup activities for the Phase\n2b trial of ATI-052 in AD and a POC trial in EoE.\n\nThe Company believes that its cash, cash equivalents and marketable securities\nwill be sufficient to fund its operations through the end of 2028, without\ngiving effect to any potential business development transactions or additional\nfinancing activities.\n\nSecond Quarter 2026 and Year-to-Date 2026\n\nNet loss was $21.5 million for the second quarter of 2026 compared to $15.4\nmillion for the second quarter of 2025. Net loss was $41.3 million for the six\nmonths ended June 30, 2026 compared to $30.5 million for the six months ended\nJune 30, 2025.\n\nTotal revenue was $1.6 million for the second quarter of 2026 compared to $1.8\nmillion for the second quarter of 2025. Total revenue was $3.6 million for the\nsix months ended June 30, 2026 compared to $3.2 million for the six months\nended June 30, 2025. The increase for the six-month period was primarily\ndriven by higher royalties earned under the Lilly and Sun Pharma license\nagreements.\n\nResearch and development (R&D) expenses were $18.1 million and $33.7 million\nfor the quarter and six months ended June 30, 2026, respectively, compared to\n$11.4 million and $23.0 million for the corresponding prior year periods. The\nincreases were primarily driven by expenses related to ATI-052, including\nproduct candidate manufacturing costs and clinical development expenses\nassociated with a Phase 1a program and Phase 1b programs in AD and asthma, as\nwell as product candidate manufacturing costs for ATI-9494.\n\nGeneral and administrative (G&A) expenses were $6.0 million and $12.8 million\nfor the quarter and six months ended June 30, 2026, respectively, compared to\n$5.4 million and $11.5 million for the prior year periods. The increases were\nprimarily due to an increase in professional and legal expenses as well as\npersonnel expenses.\n\nRevaluation of contingent consideration resulted in a $0.3 million charge for\neach of the quarter and six months ended June 30, 2026 compared to charges of\n$1.5 million and $1.8 million for the prior year periods. The decreases were\nprimarily due to changes to the probability of success for certain product\ncandidates and lower discount rates being applied to potential payments during\nthe quarter and six months ended June 30, 2025.\n\nAbout Aclaris Therapeutics, Inc.\n\nAclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company\ndeveloping a pipeline of novel product candidates to address the needs of\npatients with immuno-inflammatory diseases who lack satisfactory treatment\noptions. The Company has a multi-stage portfolio of product candidates powered\nby a robust R&D engine. For additional information, please visit\nwww.aclaristx.com and follow Aclaris on LinkedIn\n(https://www.globenewswire.com/Tracker?data=Jf5cj7CpQV5EYDwyE8-t8OqdvCdMduQv344StvXOCbAk3pIgTexL07hdgrydyERByTljmDAr_80C8FU5nPcmwyGaSrjCoXW-JEyEyq-i-WXGbhs5o39BQLDk9cdf9iBY).\n\nCautionary Note Regarding Forward-Looking Statements\n\nAny statements contained in this press release that do not describe historical\nfacts may constitute forward-looking statements as that term is defined in the\nPrivate Securities Litigation Reform Act of 1995. These statements may be\nidentified by words such as “anticipate,” “believe,” “expect,”\n“intend,” “may,” “plan,” “potential,” “will,” and similar\nexpressions, and are based on Aclaris’ current beliefs and expectations.\nThese forward-looking statements include expectations regarding its plans for\nits development programs for bosakitug, ATI-052, modzatinib (ATI-2138), and\nATI-9494, including the timing of reporting top line results from its Phase 2\ntrial of bosakitug in AD and its Phase 1b trials of ATI-052 in asthma and AD,\nthe clinical development plans for ATI-052 including the timing of initiating\na Phase 2b trial in asthma, the timing of initiating a Phase 2b trial in\nlichen planus with modzatinib, the timing to file an IND for ATI-9494, the\npotential for ATI-052 to have extended dosing, the therapeutic potential of\nits product candidates and the potential for such candidates to be\nbest-in-class, and the sufficiency of its cash, cash equivalents and\nmarketable securities to fund its operations through the end of 2028. These\nstatements involve risks and uncertainties that could cause actual results to\ndiffer materially from those reflected in such statements. Risks and\nuncertainties that may cause actual results to differ materially include\nuncertainties inherent in the conduct of preclinical and clinical studies,\nAclaris’ reliance on third parties over which it may not always have full\ncontrol, Aclaris’ ability to enter into strategic partnerships on\ncommercially reasonable terms, the uncertainty regarding the macroeconomic\nenvironment and other risks and uncertainties that are described in the\n“Risk Factors” section of Aclaris’ Annual Report on Form 10-K for the\nyear ended December 31, 2025, and other filings Aclaris makes with the U.S.\nSecurities and Exchange Commission from time to time. These documents are\navailable under the “SEC Filings” page of the “Investors” section of\nAclaris’ website at www.aclaristx.com. Any forward-looking statements speak\nonly as of the date of this press release and are based on information\navailable to Aclaris as of the date of this release, and Aclaris assumes no\nobligation to, and does not intend to, update any forward-looking statements,\nwhether as a result of new information, future events or otherwise.\n\nAclaris Therapeutics Contacts:\n\nKevin Balthaser\nChief Financial Officer\n(484) 329-2178\nkbalthaser@aclaristx.com\n\nWill Roberts\nSenior Vice President\nCorporate Communications and Investor Relations\n(484) 329-2125\nwroberts@aclaristx.com\n\n Aclaris Therapeutics, Inc. Condensed Consolidated Statements of Operations (unaudited, in thousands, except share and per share data) \n \n Three Months Ended Six Months Ended \n June 30, June 30, \n 2026 2025 2026 2025 \n \n Revenues: \n Contract research $ 356 $ 442 $ 893 $ 887 \n Licensing 1,273 1,335 2,732 2,345 \n Total revenue 1,629 1,777 3,625 3,232 \n \n Costs and expenses: \n Cost of revenue ((1)) 218 515 613 1,021 \n Research and development ((1)) 18,066 11,449 33,723 23,033 \n General and administrative ((1)) 6,048 5,386 12,791 11,525 \n Licensing 1,235 1,335 2,628 2,345 \n Revaluation of contingent consideration 300 1,500 300 1,800 \n Total costs and expenses 25,867 20,185 50,055 39,724 \n Loss from operations (24,238 ) (18,408 ) (46,430 ) (36,492 ) \n \n Other income: \n Interest income 1,761 2,018 3,275 4,184 \n Non-cash royalty income 972 961 1,826 1,794 \n Total other income 2,733 2,979 5,101 5,978 \n Net loss $ (21,505 ) $ (15,429 ) $ (41,329 ) $ (30,514 ) \n Net loss per share, basic and diluted $ (0.15 ) $ (0.13 ) $ (0.30 ) $ (0.25 ) \n Weighted average common shares outstanding, basic and diluted 142,736,848 122,580,967 135,811,921 122,486,162 \n \n (1) Amounts include stock-based compensation expense as follows: \n Cost of revenue $ (13 ) $ 190 $ 15 $ 409 \n Research and development 784 1,106 1,946 2,291 \n General and administrative 1,901 1,767 3,909 3,898 \n Total stock-based compensation expense $ 2,672 $ 3,063 $ 5,870 $ 6,598 \n \n\n\n\n Aclaris Therapeutics, Inc. Selected Consolidated Balance Sheet Data (unaudited, in thousands, except share data) \n \n June 30, December 31, \n 2026 2025 \n \n Cash, cash equivalents and marketable securities $ 170,621 $ 151,363 \n Total assets $ 179,693 $ 160,460 \n Total current liabilities $ 28,241 $ 28,645 \n Total liabilities $ 55,112 $ 57,378 \n Total stockholders' equity $ 124,581 $ 103,082 \n Common stock outstanding 139,824,273 120,499,433 \n \n\n\n\n Aclaris Therapeutics, Inc. Selected Consolidated Cash Flow Data (unaudited, in thousands) \n \n Six Months Ended \n June 30, \n 2026 2025 \n \n Net loss $ (41,329 ) $ (30,514 ) \n Depreciation and amortization 209 242 \n Stock-based compensation expense 5,870 6,598 \n Revaluation of contingent consideration 300 1,800 \n Changes in operating assets and liabilities (3,046 ) (1,176 ) \n Net cash used in operating activities $ (37,996 ) $ (23,050 ) \n \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/de2bcb21-de59-4226-bc8b-b1b747461f51)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-06T10:59:00.259680137Z","server_sent_at_ms":1786013940259},"received_at":"2026-08-06T10:59:00.668Z","source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340063/37216/en/aclaris-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-and-clinical-update.html"},"analysis":{"id":"99940","press_release_id":"110936","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Net loss widened to $21.5 million from $15.4 million year-over-year due to increased R&D spending.","Dilution of 7.3 million shares sold via ATM agreement subsequent to quarter end."],"eventType":"earnings","narrative":"Aclaris Therapeutics reported Q2 2026 revenue of $1.6 million with a net loss of $21.5 million, while subsequent ATM sales of 7.3 million shares raised $40.2 million to extend its cash runway into the end of 2028.\n\nThe company announced positive full top-line results from the Phase 1a trial of ATI-052, demonstrating a favorable safety profile and pharmacokinetics that support potential quarterly dosing.\n\nUpcoming catalysts include Phase 1b proof-of-conience data for ATI-052 in the second half of 2026 and Phase 2 results for Bosakitug in the fourth quarter of 2026.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Positive Phase 1a data for ATI-052 validates best-in-class potential while cash runway extends into 2028."},"keyFigures":{"revenue":1629000,"customDimensions":{"net_loss":"$21.5 million","cash_runway":"end of 2028","rd_expenses":"$18.1 million","atm_proceeds":"$40.2 million","cash_position":"$170.6 million","atm_shares_sold":"7.3 million"}},"quotedText":"The first half of 2026 was a period of strong execution across the organization, positioning Aclaris for an exciting second half of the year with numerous expected key catalysts","namedEntities":{"people":[{"name":"Dr. Neal Walker","role":"Chief Executive Officer and Chair of the Board of Directors"},{"name":"Kevin Balthaser","role":"Chief Financial Officer"},{"name":"Will Roberts","role":"Senior Vice President, Corporate Communications and Investor Relations"}],"products":["ATI-052","Bosakitug","ATI-045","Modzatinib","ATI-2138","ATI-9494","soquelitinib","CPI-818"],"companies":[{"name":"Aclaris Therapeutics, Inc.","ticker":"ACRS"},{"name":"Leerink Partners LLC","relationship":"underwriter"},{"name":"Cantor Fitzgerald & Co.","relationship":"underwriter"},{"name":"Lilly","relationship":"licensing partner"},{"name":"Sun Pharma","relationship":"licensing partner"}],"dollarAmounts":[{"amount":"$170.6 million","context":"cash, cash equivalents and marketable securities as of June 30, 2026"},{"amount":"$151.4 million","context":"cash, cash equivalents and marketable securities as of December 31, 2025"},{"amount":"$40.2 million","context":"aggregate gross proceeds from ATM share sales"},{"amount":"$21.5 million","context":"Q2 2026 net loss"},{"amount":"$15.4 million","context":"Q2 2025 net loss"},{"amount":"$1.6 million","context":"Q2 2026 total revenue"},{"amount":"$1.8 million","context":"Q2 2025 total revenue"},{"amount":"$18.1 million","context":"Q2 2026 R&D expenses"},{"amount":"$6.0 million","context":"Q2 2026 G&A expenses"}]},"materialImpact":{"score":4,"reasoning":"Positive Phase 1a data for lead asset ATI-052 validates best-in-class potential and supports extended dosing intervals, a significant de-risking event. The company also extended its cash runway into late 2028 via an ATM offering, removing near-term financing concerns."},"tickerRelevance":{"others":[],"primary":"ACRS"},"globalImportance":25,"audienceRelevance":30,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"small-mid-cap","eventGravity":"clinical-data-positive","sectorWeight":"biotech","cashRunwayExtension":true}},"event_type":"earnings","event_type_secondary":["clinical_trial"],"sentiment":"bullish","material_impact_score":4,"narrative":"Aclaris Therapeutics reported Q2 2026 revenue of $1.6 million with a net loss of $21.5 million, while subsequent ATM sales of 7.3 million shares raised $40.2 million to extend its cash runway into the end of 2028.\n\nThe company announced positive full top-line results from the Phase 1a trial of ATI-052, demonstrating a favorable safety profile and pharmacokinetics that support potential quarterly dosing.\n\nUpcoming catalysts include Phase 1b proof-of-conience data for ATI-052 in the second half of 2026 and Phase 2 results for Bosakitug in the fourth quarter of 2026.","key_figures":{"revenue":1629000,"customDimensions":{"net_loss":"$21.5 million","cash_runway":"end of 2028","rd_expenses":"$18.1 million","atm_proceeds":"$40.2 million","cash_position":"$170.6 million","atm_shares_sold":"7.3 million"}},"named_entities":{"people":[{"name":"Dr. Neal Walker","role":"Chief Executive Officer and Chair of the Board of Directors"},{"name":"Kevin Balthaser","role":"Chief Financial Officer"},{"name":"Will Roberts","role":"Senior Vice President, Corporate Communications and Investor Relations"}],"products":["ATI-052","Bosakitug","ATI-045","Modzatinib","ATI-2138","ATI-9494","soquelitinib","CPI-818"],"companies":[{"name":"Aclaris Therapeutics, Inc.","ticker":"ACRS"},{"name":"Leerink Partners LLC","relationship":"underwriter"},{"name":"Cantor Fitzgerald & Co.","relationship":"underwriter"},{"name":"Lilly","relationship":"licensing partner"},{"name":"Sun Pharma","relationship":"licensing partner"}],"dollarAmounts":[{"amount":"$170.6 million","context":"cash, cash equivalents and marketable securities as of June 30, 2026"},{"amount":"$151.4 million","context":"cash, cash equivalents and marketable securities as of December 31, 2025"},{"amount":"$40.2 million","context":"aggregate gross proceeds from ATM share sales"},{"amount":"$21.5 million","context":"Q2 2026 net loss"},{"amount":"$15.4 million","context":"Q2 2025 net loss"},{"amount":"$1.6 million","context":"Q2 2026 total revenue"},{"amount":"$1.8 million","context":"Q2 2025 total revenue"},{"amount":"$18.1 million","context":"Q2 2026 R&D expenses"},{"amount":"$6.0 million","context":"Q2 2026 G&A expenses"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-06T14:25:51.633Z","global_importance":25,"audience_relevance":30,"importance_components":{"tickerTier":"small-mid-cap","eventGravity":"clinical-data-positive","sectorWeight":"biotech","cashRunwayExtension":true}},"durationMs":171549,"modelName":"glm-4.7"}}